Navigation Links
Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
Date:9/14/2011

BASKING RIDGE, N.J., Sept. 14, 2011 /PRNewswire/ -- Regado Biosciences, a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at the Annual UBS Global Life Sciences Conference at the Grand Hyatt New York in New York City on Wednesday, September 21, 2011 at 3:30 p.m. EDT.  The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system REG1, including a summary of the REG1 phase 2b trial (RADAR) results.    

ABOUT REGADO BIOSCIENCES

Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent.  This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006)
'/>"/>

SOURCE Regado Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
2. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
3. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
4. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
5. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
7. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
8. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
9. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
10. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014   Zacks Equity Research highlights Epizyme (Nasdaq: ... and Panera (Nasdaq: PNRA - Free Report ) as the ... on Amicus Therapeutics (Nasdaq: FOLD - Free Report ), Sanofi ... SHPG - Free Report ). Here is a synopsis ... Day : The biotech bull market is far ...
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, is pleased ... international medical cannabis conference taking place at the ... , on October 22, 2014.  The multilingual ... such as researchers, health professionals, and patients, to ...
(Date:8/21/2014)... Memorial Hermann Health System and The University of ... partnership to provide a new level of specialized breast screening ... greater Houston area. Starting ... of professional breast radiology services for five of Memorial Hermann,s ... The Woodlands , Northeast, Southwest and Sugar ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4
... NEW YORK, Dec. 14, 2010 Reportlinker.com ... is available in its catalogue: ... Electrophysiology & Ablation Devices 2011 ... In 2010, the Asia Pacific markets for ...
... YORK, Dec. 14, 2010 Reportlinker.com announces that a ... The Clinical Trials Business ... and the outsourcing of clinical trials to lower-cost countries ... the U.S. to a 3.3% compound annual growth rate ...
Cached Medicine Technology:Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 2Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 3Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 4Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 5Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 6Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 7Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 8Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 9Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 10Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 11Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 12Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 13Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 14Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 15Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 16Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 17Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 18Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 19Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 20Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 21Reportlinker Adds The Clinical Trials Business 2Reportlinker Adds The Clinical Trials Business 3Reportlinker Adds The Clinical Trials Business 4Reportlinker Adds The Clinical Trials Business 5Reportlinker Adds The Clinical Trials Business 6Reportlinker Adds The Clinical Trials Business 7Reportlinker Adds The Clinical Trials Business 8Reportlinker Adds The Clinical Trials Business 9Reportlinker Adds The Clinical Trials Business 10Reportlinker Adds The Clinical Trials Business 11Reportlinker Adds The Clinical Trials Business 12Reportlinker Adds The Clinical Trials Business 13
(Date:8/23/2014)... 23, 2014 "I have heard female ... a urine sample," said an inventor from Lake Stevens, ... and mess-free, I came up with this urine-collection aid." ... samples to be collected from women more easily. The ... to patients and staff. The invention improves sanitation and ...
(Date:8/23/2014)... Peripheral intervention surgeries are part of ... thereby addressing the root cause of peripheral artery disease. ... the other part of the arteries where the blood ... require the use of a catheter, (which is a ... catheters are inserted through a thin cut in an ...
(Date:8/23/2014)... A team of New York researchers say ... preceded by surgery and delivered by an experienced team. Surviving ... Click here to read it now . , ... of mesothelioma patients who underwent hemithoracic (one side of ... the shape of a tumor. Patients who had surgery ...
(Date:8/23/2014)... GBI Research, the leading business intelligence provider, has ... Developed Markets to 2020 - New and Late-Stage Four-Factor ... in-depth analysis of the critical care market in the ... The report provides an estimation of market size for ... critical care indications that are being treated using the ...
(Date:8/23/2014)... Young adults in Athens, GA who find that they have a ... and call the new helpline which can offer support and guidance ... Teen Athens is a wonderful resource for an adolescent drug or ... to end substance abuse once and for all. When a young ... peers when really they should put their faith in a youth ...
Breaking Medicine News(10 mins):Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3Health News:Teenagers in Athens, GA are Locating Addiction Recovery Thanks to New Helpline 2
... own bone marrow stem cells after a heart attack ... Emory University School of Medicine physicians has found. , ... Emory University School of Medicine, presents the results Monday ... , "These results show that treatment with a patient,s ...
... highest channel-count 12-bit ADC reduces I/O pin ... SANTA CLARA, Calif., March 30 /PRNewswire/ ... mixed-signal compression solutions for intelligent data conversion, ... of analog-to-digital converters (ADCs) integrated with the ...
... Genaera Corporation (Nasdaq: GENR ) today announced ... cash resources in order to maintain the ability to ... highly selective inhibitor of PTP1B and Genaera,s lead drug ... obesity, and explore strategic alternatives. The Company will ...
... 21 is pleased to announce that Michael A. ... elected to the board of directors of the ... a 128-year old trade association representing manufacturers and ... Members were elected at the association,s March ...
... Billion Each Year According to the Better Sleep CouncilDALLAS, March ... Unfortunately, sleep is usually one of the first things people ... In a turbulent economy, nearly 30 percent of Americans ... according to a 2009 Sleep in America poll by the ...
... A health insurance protocol intended to ... barriers that lead people to receive less of needed ... result, patients ultimately require more -- and more costly ... plan members to try a first-line medication before they ...
Cached Medicine News:Health News:After heart attack, bone marrow stem cells increase blood flow within heart 2Health News:Samplify Rolls Production Quantities of Its SAM1600 Analog/Digital Converters with Real-Time Data Compression 2Health News:Samplify Rolls Production Quantities of Its SAM1600 Analog/Digital Converters with Real-Time Data Compression 3Health News:Genaera Corporation Implements Cash Conservation Plan 2Health News:Nutrition 21's President and CEO, Elected to the Consumer Healthcare Products Association Board 2Health News:Nutrition 21's President and CEO, Elected to the Consumer Healthcare Products Association Board 3Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 2Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 3Health News:Thomson Reuters Study Finds Step Therapy Programs May Increase Overall Healthcare Costs for Employers 2Health News:Thomson Reuters Study Finds Step Therapy Programs May Increase Overall Healthcare Costs for Employers 3
... from end, Cannula comes with 20cm (8 in) ... Capable of withstanding injections of viscoelastic fluids. ID-0.50mm ... lock, high pressure extension tubing set., 20cm (8 ... (Cannulas come with 20cm luer lock, high ...
Multi-sided, Sharp all around...
2.5mm...
...
Medicine Products: